scholarly journals Use of Oral Antidiabetic Drugs (Metformin and Pioglitazone) in Diabetic Patients with Breast Cancer: How Does It Effect on Serum Hif-1 Alpha and 8Ohdg Levels?

2012 ◽  
Vol 13 (10) ◽  
pp. 5143-5148 ◽  
Author(s):  
Harman Ece ◽  
Erten Cigdem ◽  
Kucukzeybek Yuksel ◽  
Dirican Ahmet ◽  
Er Hakan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Oral Antidiabetic

scholarly journals A Survey on Oral Antidiabetic Drugs available in Market for Non-complicated Diabetic Patients within Ratnagiri Region

2020 ◽  
Vol 13 (4) ◽  
pp. 399-409
Author(s):  
M. Y Agrawal ◽  
Y. P Agrawal ◽  
A Pedhavi ◽  
G Hanmante ◽  
K. Sharma
Keyword(s):  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Antidiabetic Drugs ◽  
Fixed Dose ◽  
Diabetic Patients ◽  
Pharmaceutical Companies ◽  
Type Ii ◽  
Oral Antidiabetic Drugs ◽  
Present Survey ◽  
Oral Antidiabetic

Background: This survey was designed to analyze the current oral anti-diabetic drugs prescribed for non-complicated diabetic patients within Ratnagiri region on the basis of variation in prices of same drug available in different brands. Methods: The present survey has been conducted for a period of 4 months involving number of medical stores in Ratnagiri, Maharashtra, Doctors and Patients with randomly evaluating around 650 prescriptions. A standard questionnaire was prepared containing different questions; based on patient’s data (such as age, gender, disease history and medications), Doctor’s data (commonly prescribed drug, combination) and chemist data (available alternatives, cost and most selling brands). Results: Statistical analysis of patients data revels that there were 47.5% patients are in between the ages of 50 to 60 years and 92.5 % patient depends on oral antidiabetic drugs. Hypertension was the most common complication found among them (54%). Data from Doctor’s during survey suggested Metformin as mostly prescribed drug to patients having type- II Diabetes Mellitus as a single entity or in fixed dose combinations with Glimiperide or Gliclazide. An exhaustive survey over medical shops revealed that many brands of Metformin and Metformin in combination with Glimiperide or Gliclazide are available in market, but Glycomate (Metformin), Glycomate GP-1 (Metformin and Glimiperide) and Glizid-M (Metformin and Gliclazide) is mostly prescribed by Doctors and sold by Chemist though their cheapest alternatives are available in market. Cost analysis indicates that, wide variation in price of several brands (75-87 %) for oral anti-diabetics. Annual Turnover of these products in Indian domestic market indicates dominance of USV Pvt. Ltd. and Mankind Ltd. over other Pharmaceutical companies. Conclusions: This report will create better awareness among people for the availability of various brands of same anti-diabetic drug and also motivate our physicians to prescribe the economic products.

scholarly journals Liu Wei Di Huang Wan and the Delay of Insulin Use in Patients with Type 2 Diabetes in Taiwan: A Nationwide Study

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Hsin-Hung Chen ◽  
Chien-Tung Wu ◽  
Yueh-Ting Tsai ◽  
Chun-Wei Ho ◽  
Ming-Chia Hsieh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Lower Risk ◽  
Cox Proportional Hazards Model ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Research Database ◽  
Oral Antidiabetic Drugs ◽  
Oral Antidiabetic ◽  
Insulin Use

Introduction. Patients with type 2 diabetes are widely prescribed metformin for controlling blood glucose levels to avoid related comorbidities. In Taiwan, traditional Chinese medicine (TCM) is also commonly used, especially Liu Wei Di Huang Wan (LWDHW), which has been reported to delay the occurrence of kidney failure. However, the effect of combinational therapy of TCM and oral antidiabetic drugs is still unclear. This study aims to estimate their efficacy in delaying insulin use. Materials and Methods. This case-control study was conducted using one million randomized samples from the National Health Insurance Research Database in Taiwan. The effects of TCM and LWDHW were estimated using the Cox proportional hazards model. Results. In this study, 70,036 diabetic patients were enrolled; of them, 17,451 (24.9%) used insulin, while the rest (52,585, 75.1%) did not. TCM users had a lower risk for insulin use (HR: 0.58, 95% CI: 0.56–0.60). LWDHW users had a lower risk compared with patients who used other TCM (HR: 0.86, 95% CI: 0.82–0.90) and presented a dose-dependent effect. Conclusion. The use of LWDHW and oral antidiabetic drugs is highly associated with the delay in the use of insulin. Clinical practitioners may take them into consideration when treating patients with type 2 diabetes.

Drug interactions in diabetics

1979 ◽  
Vol 17 (10) ◽  
pp. 37-40
Keyword(s):  
Blood Glucose ◽  
Drug Interactions ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Hypoglycaemic Agents ◽  
Oral Antidiabetic

Drugs taken by diabetic patients for reasons other than the control of blood glucose may affect the response to insulin or oral antidiabetic drugs. Drugs may also interfere with tests for glucose or ketones in the urine or those estimating glucose in the blood. In Britain about a quarter of a million people take hypoglycaemic agents and many others are treated by diet alone, so it is clearly important to be aware of these special problems.

Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs

2011 ◽  
Vol 152 (37) ◽  
pp. 1471-1476 ◽  
Author(s):  
György Jermendy
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Antidiabetic Drugs ◽  
Dose Titration ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Dipeptidyl Peptidase 4 ◽  
Oral Antidiabetic ◽  
Dipeptidyl Peptidase 4 Inhibitors

Nearly 90% of the diabetic patients are suffering of type 2 diabetes while approximately 60-65% of patients with type 2 diabetes are treated with oral antidiabetic drugs. In the last couple of years a new treatment option, namely incretin-based therapy, became available. The dipeptidyl-peptidase-4-inhibitors (gliptins) are designated as incretin enhancers. Using gliptins, sustained glycemic control can be achieved without gaining weight and increasing the risk of hypoglycemia. All gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin) can be used as tablets without a need for dose titration. For treating patients with type 2 diabetes, gliptins can primarily be used in combination with metformin. Orv. Hetil., 2011, 152, 1471–1476.

scholarly journals Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38)

2015 ◽  
Vol 7 (3) ◽  
pp. 386-395 ◽  
Author(s):  
Azuma Kanatsuka ◽  
Yasunori Sato ◽  
Koichi Kawai ◽  
Koichi Hirao ◽  
Masashi Kobayashi ◽  
...  
Keyword(s):  
Clinical Features ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Type 2 Diabetic Patients ◽  
Oral Antidiabetic ◽  
Type 2 Diabetic

scholarly journals Increased osteoprotegerin level is associated with impaired cardiovagal modulation in type-2 diabetic patients treated with oral antidiabetic drugs

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
M. R. Jasmine ◽  
Nivedita Nanda ◽  
Jayaprakash Sahoo ◽  
S. Velkumary ◽  
G. K. Pal
Keyword(s):  
Body Composition ◽  
Low Frequency ◽  
Antidiabetic Drugs ◽  
Rate Pressure Product ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Type 2 Diabetic Patients ◽  
Oral Antidiabetic ◽  
Patients With Diabetes

Abstract Background An increased osteoprotegerin (OPG) level has been reported in both type-2 diabetes mellitus (T2DM) and cardiovascular diease (CVD) that are linked to sympathovagal imbalance (SVI). We explored the link of osteoprotegerin with cardiovagal modulation in T2DM. Methods We assessed fasting serum OPG, high-sensitive C-reactive protein (hsCRP), glucose, insulin and lipid profile in patients having T2DM receiving oral antidiabetic drugs (OAD) (n = 42) compared with age, gender and body composition-matched healthy participants without diabetes (n = 42). Rate pressure product (RPP), spectral indices of heart rate variability (HRV) and body composition were recorded in both the groups. Association of HOMA-IR and OPG with various parameters were assessed. Results Osteoprotegerin, HOMA-IR, hsCRP, coronary lipid risk factor were significantly increased, markers of cardiovagal modulation (TP, SDNN, RMSSD) were considerably decreased, ratio of low-frequency to high-frequency (LH-HF ratio), the indicator of SVI, and RPP, the marker of myocardial work stress were significantly higher in patients with diabetes, suggesting an overall elevated CVD risks in them. HOMA-IR was correlated with RMSSD, lipid risk factors and OPG. Rise in OPG was correlated with decreased cardiovagal modulation in patients with diabetes. There was significant contribution of OPG in decreasing TP, suggesting impaired cardiovagal modulation. Conclusion T2DM patients receiving OAD had higher cardiometabolic risks compared to age, gender and body composition-matched healthy individuals. Increased level of OPG is linked to decreased cardiovagal modulation in T2DM patients.

scholarly journals Oral antidiabetic drugs in chronic renal diseases

2012 ◽  
Vol 153 (44) ◽  
pp. 1727-1731
Author(s):  
Anikó Somogyi
Keyword(s):  
Kidney Diseases ◽  
Antidiabetic Drugs ◽  
Renal Diseases ◽  
Diabetic Patients ◽  
Oral Antidiabetic Drugs ◽  
Chronic Kidney Diseases ◽  
Dipeptidyl Peptidase 4 ◽  
Oral Antidiabetic ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Label Information

Decline in renal function may increase plasma concentration of several drugs – including oral antidiabetics – with a possible need for dose adjustment in this patient population. In this review, the pathophysiology and progression of diabetic kidney diseases is summarized. Guidance is given about appropriate administration of oral antidiabetic drugs in chronic kidney diseases, based on approved product label information. In addition to pioglitazon, recent availability of the new dipeptidyl peptidase-4 inhibitor linagliptin provides another option for diabetic patients with renal impairment without the need for dose reduction due to its predominant enterohepatic elimination. Orv. Hetil., 2012, 153, 1727–1731.

Sign in / Sign up

Export Citation Format

Share Document